As with many other companies AbbVie Inc. (NYSE:ABBV) makes use of debt. But should shareholders be worried about its use of ...

AbbVie Inc. closed $6.48 below its 52-week high ($199.95), which the company reached on September 3rd.

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

BARCELONA, Spain — New phase 3 findings revealed that most patients with newly diagnosed high-risk endometrial cancer did not benefit from receiving adjuvant immunotherapy alongside chemotherapy ...

The next frame shows the Ubrelvy logo in the backstage hallway along with a blue lit path. Frames six to seven then show Serena Williams walking down the blue lit path, no longer exhibiting migraine ...

Recent research highlights the potential of microRNAs as cost-effective and less invasive biomarkers for early diagnosis and ...

The stock's fall snapped a two-day winning streak.

The Vanguard Dividend Appreciation ETF has performed well compared to other income ETFs. The fund has a 12.1% annualized ...

With the Federal Reserve potentially cutting interest rates for the first time in over four years, uncertainty looms in the ...

Daniel Reiner, an investor in companies worth billions of dollars, was found dead in a Pend Oreille County lake he owned with ...

The global anxiety disorders and depression treatment market, valued at approximately USD 11.2 billion in 2021, is on track ...